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Abstract
Postmenopausal women with elevated serum sex steroids have an increased risk of breast cancer.
Mostofthisriskisbelievedtobeexertedthroughbindingofthesexsteroidstotheirreceptors.Forthe
ﬁrsttime,weinvestigatetheassociationofestrogenreceptor(ER)andandrogenreceptor(AR)serum
bioactivity (SB) in addition to hormone levels in samples from women with breast cancer collected
before diagnosis. Two hundred postmenopausal women participating in the UKCollaborative Trial of
Ovarian Cancer Screening who developed ER-positive breast cancer 0.6–5 years after sample
donation were identiﬁed and matched to 400 controls. ER and AR bioassays were used to measure
ERa,E R b, and AR SB.Androgen andestrogen levels were measured withimmunoassays.Subjects
were classiﬁed according to quintiles of the respective marker among controls and the associations
between SB and hormones with breast cancer risk were determined by logistic regression analysis.
ERaandERb SB were signiﬁcantly higher before diagnosis compared with controls, while estrogens
showednodifference.WomenhadatwofoldincreasedbreastcancerriskifERaSB(oddsratio(OR),
2.114; 95% conﬁdence interval (CI), 1.050–4.425; PZ0.040) was in the top quintile O2 years before
diagnosis or estrone (OR, 2.205; 95% CI, 1.104–4.586; PZ0.029) was in the top quintile !2y e a r s
before diagnosis. AR showed no signiﬁcant association with breast cancer while androstenedione
(OR, 3.187; 95% CI, 1.738–6.044; PZ0.0003) and testosterone (OR, 2.145; 95% CI, 1.256–3.712;
PZ0.006) were signiﬁcantly higher compared with controls and showed a strong association with an
almost threefold increased breast cancer risk independent of time to diagnosis. This study provides
further evidence on the association of androgens and estrogens with breast cancer. In addition, it
reportsthathighERbutnotARSBisassociatedwithincreasedbreastriskO2yearsbeforediagnosis.
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Introduction
Breast cancer remains one of the leading causes of
cancer death among women despite the huge progress
that has been made in treatment (Santen et al. 2007,
Weigel & Dowsett 2010). Many risk factors for
postmenopausal breast cancer are suggested to mediate
their effect through a hormonal mechanism (Henderson
& Feigelson 2000). The largest meta-analysis com-
bining nine prospective studies demonstrated that
postmenopausal women with serum estrogen and
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increased risk of breast cancer (Key et al. 2002). Since
then, a number of studies have reported conﬂicting
resultsontheassociationofserumsexsteroidhormones
and breast cancer risk (Lamar et al. 2003, Manjer et al.
2003, Onland-Moret et al. 2003, Missmer et al. 2004,
Zeleniuch-Jacquotte et al. 2004, 2005, Kaaks et al.
2005, Tworoger et al. 2005, Adly et al. 2006, Beattie
et al. 2006, Eliassen et al. 2006, Sieri et al. 2009,
Baglietto et al. 2010). All these reports have used
conventional immunoassays to measure hormone
levels. In the past few years, bioactivity assays for
steroid hormone receptors have been described,
enabling quantiﬁcation of total hormone action (Paris
et al. 2002, Sievernich et al. 2004, Roy et al.2 0 0 6 ). As
estrogen and androgen hormones exert their effects
through binding to sex steroid hormone receptors, we
previously hypothesized that bioactivity assays might
be an attractive alternative for breast cancer risk
assessment. We found that estrogen receptor a (ERa)
and ERb serum bioactivity (SB) are independently
associatedwithbreastcancerusingsamplescollectedat
diagnosis (Widschwendter et al. 2009).
To better understand the long-term effect of sex
steroids and bioactivity of their receptors on breast
cancer risk, it is crucial to examine levels many years
before diagnosis. We were able to explore this issue
using the UK Collaborative Trial of Ovarian Cancer
Screening (UKCTOCS) biobank. Women recruited to
the trial between 2001 and 2005 provided blood
samples for secondary studies and continue to be
followed up by cancer registration and self-reporting
(Menon et al. 2008, 2009). We report on a nested case–
control study using serum samples donated between 6
months and 5 years before diagnosis by women who
developed breast cancer after joining the trial and
healthy women who had not developed the disease. SB
of ERa and ERb and androgen receptor (AR) were
measured using a yeast-based assay along with ﬁve sex
steroid hormones (estradiol (E2), estrone, androstene-
dione, testosterone, and dehydroepiandrosterone
sulfate (DHEAS)), free E2 (fE2) and free testosterone
(fT; calculated by the mass action law), and sex
hormone-binding globulin (SHBG) using conventional
immunoassays to examine their association with breast
cancer risk.
Materials and methods
Cohort
The subjects were participants in the UKCTOCS, a
multicenter randomized controlled trial of ovarian
cancer screening in England, Wales, and Northern
Ireland, coordinated by the Gynecological Cancer
Research Centre at University College London
(UCL). Women aged 50–74 were recruited through
random invitation from age/sex registers of 27
participating Primary Care Trusts. At recruitment,
each woman donated a blood sample, ﬁlled in a
baseline questionnaire, and provided written consent
giving permission to access their medical records and
use their data/samples in future studies. The ques-
tionnaire included questions on demographics, height,
weight, parity, hysterectomy, tubal ligation, treatment
for infertility, contraceptive pill, hormone replacement
treatment (HRT), and previous history of any cancer
and family history of ovarian/breast cancer (Menon
et al. 2008).
Selection of the study sample
All participants are being followed up through a
‘ﬂagging study’ with the NHS Information Centre for
Health and Social Care. Up-to-date cancer registration
data were obtained from the agencies on 2nd February
2009 (median follow-up 5.681 years and interquartile
range (IQR), 1.284 years). For conﬁrmation of
diagnosis, their treating physician was sent a ques-
tionnaire requesting information regarding their diag-
nosis (histology) and treatment. Two hundred women
who developed ER-positive invasive breast cancer
after joining the UKCTOCS and were not on HRT
treatment at recruitment and had donated a serum
sample between 6 months and 5 years before diagnosis
were chosen as ‘cases’ for this study. Each breast
cancer case was age matched with two women who had
no history of breast cancer (controls) at last follow-up
and had donated serum samples on the same day and in
the same clinic. The UKCTOCS was approved by the
UK North West Multicentre Research Ethics Commit-
tees (North West MREC 00/8/34). Ethical approval for
this nested case–control study was obtained from the
Joint UCL/UCLH Committees on the Ethics of Human
Research (22nd February 2007, 06/Q0505/102).
Serum sample processing
The blood samples were collected into Griener Bio one
gel tubes (Cat no: 455071) at the centers, shipped
overnight to the central laboratory, and centrifuged at
2000 g for 10 min. The serum was removed from the
cells within 56 h of sample collection and was frozen
using a two-stage freezing process: 12 h at K80 8C and
then placed in liquid nitrogen (vapor phase) at
K180 8C. A novel semi-automated system aliquoted
serum in 500 ml straws was then heat sealed, bar coded,
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straws were retrieved, one for the measurement of
hormone levels and one for the bioactivity assays. The
samples were only thawed once, at the time of the
assay.
Sex steroid hormone receptor bioactivity using
bioassay systems
Sex steroid hormone receptor bioactivity was
measured using a yeast-based reporter gene assay
that not only determines whether a chemical binds to
the receptor, but also whether estrogen- or androgen-
dependent gene expression is stimulated. The assay has
been described previously (Widschwendter et al.
2009). Brieﬂy, the genetically modiﬁed yeast cells
were incubated in a deﬁned test medium with the
reference substance E2 for ERa and ERb and
dihydrotestosterone for AR test samples and negative
controls. At the end of the incubation period the
developed green ﬂuorescence was determined and
corrected for cell density, optical density (OD) of the
cell suspension and blanks. The cell growth was
determined by measuring the light absorption at
600 nm and GFP-ﬂuorescence by measuring GFP at
535 nm, speciﬁc OD and ﬂuorescence at tZ0 and tZ
16.5 h for ERa and ERb and tZ24 h for AR in each of
the 96 wells. Tests were considered as valid if the
turbidity of the negative control culture increased ﬁve
times during the incubation period. The control culture
showed no ﬂuorescence. The bioactivity was
determined by comparison of the ﬂuorescence
development in test cultures vs the calibration curve.
The dose–response curves of the reference values were
ﬁtted using the Hill equation ﬁt and the R-function. The
analysis was performed blind and cases and controls
were randomly mixed. Tests were carried out with two
replicates at a time on two different days (four readings
in total). The lower detection limit for the ER SB is
5 pg/ml and for AR SB is 0.2 ng/ml. The inter-assay
coefﬁcients of variation were lower than 20%.
Hormone levels using immunoassay systems
For E2, testosterone, DHEAS, and SHBG kits were
obtained from Roche and the samples were run on an
Elecsys 2010 analyzer (Roche Diagnostics GmbH).
AndrostenedionelevelsweremeasuredusinganELISA
kit on DPC IMMULITE 2500 analyzer (Siemens
Medical Solutions Diagnostics, Munich, Germany).
For estrone ELISA kit was obtained from DRG (DRG
Instruments GmbH, Marburg, Germany). The samples
were analyzed blind and cases and controls were
randomly mixed in batches using a single lot number
of reagent and calibrator. One scientist did all the
measurements. Two levels of quality control (QC)
material were analyzed with each run on the analyzer
and standard Westgard rules applied. Two levels of QC
material were included on each plate for the manual
ELISA assays. FE2 and fT were calculated using the
equation based on the law of mass action (Vermeulen
et al. 1999).
Statistical analysis
Mean and median levels of sex steroid hormones, ERa
and ERb and AR SB were calculated for all breast
cancer samples and controls. Differences in the
medians between the groups were tested for statistical
signiﬁcance using the Kruskal–Wallis test. Corre-
lations between sex steroid hormones, and ERa and
ERb and AR SB among cases and controls were
assessed by the Spearman’s rank correlation coefﬁ-
cient. Subjects were classiﬁed according to quintiles of
the respective marker among controls. The associ-
ations between ERa,E R b, AR SB, hormone levels and
the risk of breast cancer were determined by logistic
regression analysis controlling for age. Finally, SB
levels of each receptor were controlled for all
hormones and SB in regression models to estimate
their independent associations with breast cancer risk.
Results
The median age of the 200 women with breast cancer
(cases) was 61.33 (IQR, 11.32) and 62.33 (IQR, 9.57),
in the 400 healthy women (matched controls). Breast
tumor characteristics of the cases were similar to a
typical breast cancer cohort (Table 1). None of the
traditional risk factors (family history, age at
menarche, menopause, number of pregnancies, contra-
ceptive pill use, hysterectomy, infertility, body mass
index, and height) were signiﬁcantly different between
cases and controls except for fallopian tube ligation
(odds ratio (OR) for breast cancer, 0.57; 95%
conﬁdence interval (CI), 0.35–0.94; PZ0.029).
Usingallsamples,correlationsofsexsteroidhormones
and SHBG with sex steroid receptor SB were investi-
gated.FE2andfTshowedastatisticalsigniﬁcantpositive
correlation and SHBG a negative correlation with ERa,
ERb, and AR SB. All three sex steroid hormone receptor
SB correlated with each other (Table 2).
For the purposes of the analysis, women were
stratiﬁed into groups based on whether their sample
was obtained 6 months to %2o rO2–5 years before
breast cancer diagnosis. We decided to use the same
cut off as that used in the largest reanalysis by
Endocrine-Related Cancer (2012) 19 137–147
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studies. For those women who had given a sample
O2 years before diagnosis, the serum androgens:
androstenedione, testosterone, and fT, and both ERa
and ERb SB showed signiﬁcant differences between
cases and controls (Table 3). We further analyzed the
data based on quintiles with subjects being classiﬁed
according to quintiles of the respective marker among
controls. Women with serum ERa bioactivity in the top
quintile had a 2.15 (95% CI, 1.05–4.43; P!0.05)-fold
breast cancer risk (Table 4). No association was shown
between breast cancer risk and ERb and AR SB
(Table 4). Women with serum levels in the top quintile
of androstenedione, testosterone, and fT were signi-
ﬁcantly associated with 4.36 (95% CI, 1.87–11.55)-,
2.53 (95% CI, 1.24–5.41)-, and 2.84 (95% CI, 1.30–
6.64)-fold risk for breast cancer respectively (Table 4).
Other hormones tested did not show any signiﬁcant
association with breast cancer risk (Table 4). To test
whether serum sex steroid receptor bioactivity is
independently associated with breast cancer logistic
regression analysis was performed adjusting for all
hormones and SB. ERa bioactivity was independently
associated with breast cancer after adjustment for all
hormones and AR and borderline signiﬁcant after
adjustment for ERb for those women who had given a
sample O2 years before diagnosis. Furthermore, after
adjustment for all hormones and SB both androstene-
dione and testosterone were independently associated
with breast cancer risk (data not shown).
For those women who had given samples %2 years
before diagnosis, ERa,E R b, and AR SB did not show
any signiﬁcant association with breast cancer and did
not predict risk (Tables 3 and 4). This observation did
not change after adjusting for all hormones and SB.
SHBG and serum fT showed signiﬁcant differences
between cases and controls (Table 3). Serum levels in
the top quintile of androstenedione, testosterone, fT,
and estrone were signiﬁcantly associated with 2.49
(95% CI, 1.20–5.46)-, 1.870 (95% CI, 0.97–3.70)-,
2.02 (95% CI, 0.09–4.24)-, and 2.21 (95% CI, 1.10–
4.59)-fold risk for breast cancer respectively (Table 4).
The association of androstenedione, testosterone, and
estrone with breast cancer risk remained statistically
signiﬁcant after adjustment for all hormones and SB
(data not shown). In addition, women who had serum
levels in the top quintile of SHBG had a reduced risk of
breast cancer (0.32; 95% CI, 0.13–0.73; PZ0.001;
Table 4). Other hormones tested did not show any
signiﬁcant association with breast cancer risk
(Table 4).
Analysis was also undertaken combining both
groups. For the 11 hormones and sex steroid receptor
SB, differences between cases and controls were
observed for serum androstenedione, testosterone,
and fT levels (Table 3). ERa,E R b, and AR SB did
not show any signiﬁcant association with breast cancer
and did not predict risk (Table 4). This observation did
not change after adjusting for all hormones and SB.
Women who had serum levels in the top quintile of
androstenedione, testosterone, and fT had 3.187 (95%
CI, 1.74–6.04)-, 2.15 (95% CI, 1.26–3.71)-, and 2.35
(95% CI, 1.33–4.26)-fold breast cancer risk respect-
ively (Table 4). The association of androstenedione
and testosterone with breast cancer risk remained
statistically signiﬁcant after adjustment for all hor-
mones and SB (data not shown). Other hormones
examined did not show any signiﬁcant association with
breast cancer risk (Table 4).
Discussion
Thestudyaddstotheongoingefforttobetterunderstand
the association of sex steroid hormones with breast
cancer. This report is the ﬁrst we are aware of that
examines the role of sex steroid hormone receptor
Table 1 Characteristics of the breast cancer cases
No.
Histology
Ductal 156
Ductal and lobular 6
Lobular 25
Mucinous 1
NST 3
Tubular 1
Other 8
Stage
19 6
23 9
31 0
Unknown 55
Grading
13 2
2 111
35 3
Unknown 4
Estrogen receptor (ER)
ER-positive 200
Progesterone receptor (PR)
PR-negative 32
PR-positive 100
Unknown 68
HER2
HER2-negative 79
HER2-positive 16
Unknown 105
NST, no speciﬁed type; HER2, human epidermal growth factor
receptor 2.
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hormones using conventional immunoassays before
breast cancer diagnosis within a well-deﬁned cohort of
womendiagnosedwithestrogen-sensitivebreastcancer
and healthy controls. Serum ERa and ERb were
signiﬁcantly higher in postmenopausal women before
diagnosis, with women having a twofold increased
breast cancer risk if ERa SB was in the top quintile
more than 2 years before diagnosis. Estrogens were not
found to be signiﬁcantly different between cases and
controls but women with estrone levels in the top
quintile !2 years before diagnosis had a twofold
increased breast cancer risk. Testosterone and andros-
tenedione were signiﬁcantly higher among cases
compared with controls and showed a strong associ-
ation with an almost threefold increased breast cancer
risk independent of time to diagnosis. However, this
was not reﬂected in serum AR bioactivity that was not
associated with breast cancer.
The strengths of this study are 1) the nested case–
control design within a well-deﬁned cohort with
prospective identiﬁcation of breast cancer cases, 2)
use of standardized protocol for serum sample
collection and storage with protocol adherence
conﬁrmed by the lack of any difference in mean
hormone or steroid receptor SB levels between the
different trial centers (data not shown), 3) conﬁrmation
of breast cancer diagnosis and receptor status from the
treating physicians that eliminated possible misidenti-
ﬁcation of cases from use of cancer registry data or
self-reporting alone, 4) well-deﬁned homogenous cases
through use of strict eligibility criteria (women not on
HRT with ER-positive invasive breast cancer), and
5) selection of controls from the same population as
those with breast cancer.
Our observations that ERa and ERb SB were
signiﬁcantly higher in postmenopausal women before
diagnosis of invasive ER-positive breast cancer extend
our previous ﬁndings of elevated bioactivity in women
with breast cancer at the time of clinical diagnosis
(Widschwendter et al. 2009). The receptor SB showed
statistically signiﬁcant correlation with fE2 that has the
highest known afﬁnity for ERa (Lippman et al. 1977).
This is in keeping with the meta-analysis results that
women with high E2 levels more than 2 years before
diagnosishadahigherbreastcancerriskcomparedwith
those who had high E2 levels closer to diagnosis (Key
et al. 2002). Serum receptor activation is probably
modulated by other surrogates as well. In our previous
study,receptorSBwastwo-tothreefoldhigherthanthe
actual E2 concentration (Widschwendter et al. 2009).
This may explain the increased breast cancer risk in
Table 2 Spearman’s correlation coefﬁcients among estrogens, androgens, SHBG, and serum bioactivity of estrogen and androgen
receptors for cases and controls combined
Correlation coefﬁcients
ERa Erb AR Body mass index n
Estradiol (E2) 0.059 0.062 0.055 0.313 573
PZ0.181 PZ0.16 PZ0.214 PZ0.000
Free E2 0.124 0.148 0.109 0.444 555
PZ0.005 PZ0.001 PZ0.013 PZ0.000
Estrone 0.025 0.066 0.080 0.098 582
PZ0.565 PZ0.132 PZ0.067 PZ0.021
Androstenedione 0.058 0.081 0.002 0.097 581
PZ0.186 PZ0.064 PZ0.963 PZ0.022
Testosterone 0.024 0.051 0.034 0.132 575
PZ0.592 PZ0.244 PZ0.443 PZ0.001
Free testosterone 0.102 0.139 0.090 0.545 558
PZ0.021 PZ0.002 PZ0.041 PZ0.000
DHEAS 0.020 0.010 0.012 0.010 580
PZ0.647 PZ0.814 PZ0.785 PZ0.803
SHBG K0.220 K0.242 K0.128 K0.423 580
PZ0.005 PZ0.000 PZ0.004 PZ0.000
ERa 0.507 0.307 0.074 588
PZ0.000 PZ0.000 PZ0.073
ERb 0.507 0.330 0.126 589
PZ0.000 PZ0.000 PZ0.002
AR 0.307 0.330 0.045 588
PZ0.000 PZ0.000 PZ0.279
AR, androgen receptor; DHEAS, dehydroepiandrosterone sulfate; ER, estrogen receptor; SHBG, sex hormone-binding globulin.
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years before diagnosis in the absence of a correlation
with individual estrogens. The potential advantage of
using SB assays for steroid receptors is that their levels
reﬂect the sum of all the factors in the serum that
transactivate the two different ERs. Furthermore,
previous data based on cell-based assays have shown
ERb to be less active on gene transcription than ERa
(Fox et al. 2008). This could explain our ﬁndings that
while ERb SB is different among cases and controls,
levels in the top quintile are not associated with an
increased breast cancer risk.
Lack of association between E2 and breast cancer
risk may also be attributed to the assayperformance.E2
levels in postmenopausal women are very low and over
the last few years there have been concerns about the
sensitivity of direct immunoassays to measure such
hormones (Santen et al. 2007). Estrone (the main
circulating estrogen in postmenopausal women) in the
top quintile was associated with increased risk 2 years
before breast cancer diagnosis. This observation of
estrone rather than E2 having a stronger association
with increased breast cancer risk has been reported by
other authors (Zeleniuch-Jacquotte et al. 2004). After
adjustment for all the other hormones and SB, estrone
remained associated with breast cancer risk indicating
an independent role. It has weak and low afﬁnity to
ERa (Bonoﬁglio et al. 1999) and may exert its effect on
breast carcinogenesis by inducing ERK phosphoryl-
ation via binding to the estrogen G protein-coupled
receptor 30 (GPR30; Maggiolini et al. 1999b, Yager
2000). If a signiﬁcant ER-independent pathway is
conﬁrmed, it could have implications for hormone
therapy in prevention and treatment of breast cancer in
postmenopausal women.
Androstenedione and testosterone were associated
with an almost threefold increase in breast cancer risk
independent of time from diagnosis. The meta-analysis
of nine studies in postmenopausal women conﬁrmed
that high testosterone and androstenedione levels were
associated with increased risk (Key et al. 2002). The
more recent report from EPIC (Kaaks et al. 2005) also
conﬁrmed that androgens were associated with breast
risk independent of time to diagnosis. After adjustment
for estrogens, the association of the androgens with
breast cancer risk remained, indicating that they may
have an estrogen-independent effect on the breast, an
observation that has been reported by other authors
(Key et al. 2002, Missmer et al. 2004, Kaaks et al.
2005). One of the possible pathways that androgens
may inﬂuence breast cancer risk is by directly binding
to AR, stimulating or inhibiting breast cell growth
(Maggiolini et al. 1999a, Cox et al. 2006) but we were
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www.endocrinology-journals.org 144unable to demonstrate such an association. While fT is
the best ligand of AR, androgens have also been shown
to bind and activate ERs (Maggiolini et al. 1999a). Our
data showing a statistically signiﬁcant correlation
between fT and both ERs favor the view for the
existence of the latter pathway where androgens
promote breast cell proliferation by binding directly
to ER.
To summarize, our ﬁndings provide further evidence
of the association between sex steroid hormones and
breast cancer risk. Testosterone and estrone were
shown to be associated with increased breast cancer
risk. Based on that, it would be interesting to evaluate
the association of key enzymes in steroidogenesis such
as aromatase and 17b-hydroxysteroid dehydrogenases
and breast cancer. In addition, our report provides
novel insight into the role of sex steroid receptor SB in
breast cancer with ER but not AR SB associated with
increased risk more than 2 years before diagnosis.
Further development of these assays might appear
promising for giving greater insight into the role of sex
hormones in relation to breast cancer risk but on the
basis of the current results the assays do not appear to
have a stronger association with breast cancer risk
compared with this and previous studies using
conventional assays. If ER SB results are validated in
other studies, it may also prove beneﬁcial in
individualizing and monitoring breast cancer chemo-
preventive strategies using antiestrogens such as
tamoxifen (Cuzick et al. 2003), raloxifene (Fabian &
Kimler 2005), and aromatase inhibitors (Kalidas &
Brown 2005).
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